Home
Features
-
Blockbuster Contenders: Drugs to Watch in 2025
Which new market entrants should be on the industry’s radar in 2025? What new products, recently or expected to launch in 2025, show blockbuster potential? A look at the leading blockbuster contenders.
-
What is Next in Drug Pricing Reforms for the US?
Under a new US Administration, will drug-pricing reforms that call for the US government to negotiate prices for certain drugs continue? Will these reforms stay in play, and which products may be affected?
-
SPONSORED CONTENT
Overcoming Barriers To Patient Adherence With A Novel Dosage Form
-
SPONSORED CONTENT
OLON GROUP ANNOUNCES THE ACQUISITION OF GTP BIOWAYS GROUP
-
SPONSORED CONTENT
Global Scenario: Opportunities and Challenges in Peptides
DCAT MEMBER COMPANY COMMUNITY
-
New! ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement…
-
New! Production to Prescription Podcast: Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?
What will be the key issues in the CDMO space for parenteral drug manufacturing in 2025? The latest episode of DCAT Value Chain Insights’ original podcast Production to Prescription, examines…
-
New Member Company Alert
Welcome to our Newest Member Companies! We are pleased to welcome the following companies to our DCAT Member Community. To View all DCAT member companies visit the Member Directory. From…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…